Results 51 to 60 of about 9,389 (136)

Comparing Mean Platelet Volume Values in Patients with Recurrent Aphthous Stomatitis and Patients with Behcet’s Disease

open access: yesBezmiâlem Science, 2018
Objective:Platelets play an important role in the pathogenesis of disorders associated with the local or systemic inflammation. Mean platelet volume (MPV) is a marker for platelet activation, and larger platelets are more activated.
Dilek BIYIK ÖZKAYA   +2 more
doaj   +1 more source

Clinical Assessment and Cytomorphometric Analysis of Buccal Mucosal Cells in Behçet’s Disease Patients

open access: yesJournal of Baghdad College of Dentistry, 2019
Background: Behçet’s disease (BD) is a disorder of systemic inflammatory condition. Its important features are represented by recurrent oral, genital ulcerations and eye lesions. Aims.
Dalya Mohammed, Layla S Yas
doaj   +1 more source

Effect of Hyaluronic Acid on Palatal Wound Healing—A Randomized Crossover Clinical Trial

open access: yesClinical Oral Implants Research, EarlyView.
ABSTRACT Aim To assess the effect of a hyaluronic acid (HyA) containing gel on patient‐related outcomes (PRO) and wound healing after palatal punch‐biopsy representing a free gingival graft. Material and Methods A punch‐biopsy (6 mm diameter, 2 mm thickness) was harvested from one side of the palate at Day 0 and from the contralateral side at Day 21 ...
Madeleine Dahi   +5 more
wiley   +1 more source

Correlation of Otorhinolaryngologic Symptoms with Physical Findings in Behçet’s Disease

open access: yesB-ENT, 2015
Correlation of Otorhinolaryngologic Symptoms with Physical Findings in Behçet’s Disease. Objective: Behçet’s disease is a chronic systemic inflammatory disease of unknown etiology.
A. Meric   +5 more
doaj   +2 more sources

Lipid Storage Myopathy in Behçet's Disease: A Rare Cause of Elevated Serum Creatine Kinases Levels

open access: yesCase Reports in Rheumatology, 2012
Muscular involvement in Behçet’s disease is rare and there are only a few case reports in the literature. The causes of elevated muscle enzymes in a patient with Behcet’s disease are many, including myositis, drug-induced myopathy, metabolic myopathy ...
Sedat Yilmaz   +6 more
doaj   +1 more source

Primary Cutaneous Gamma‐Delta T‐Cell Lymphoma Complicating Long‐Standing Immunosuppressed Dermatomyositis

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Primary cutaneous gamma‐delta T‐cell lymphoma (PCGD‐TCL) is a rare cytotoxic lymphoma with key oncogenic drivers in the JAK/STAT pathway. Also primarily involving the subcutaneous adipose tissue, subcutaneous panniculitis‐like T‐cell lymphoma (SPTCL) is more frequently encountered in scenarios of autoimmune disorders.
Bennett Christie‐Nguyen   +6 more
wiley   +1 more source

MEFV Gene Mutations in Behçet’s Disease

open access: yesEurasian Journal of Medicine, 2019
Behçet's disease is a chronic inflammatory multisystemic disorder of unknown cause, characterized by orogenital ulcers, uveitis, skin lesions, vascular, locomotor, pulmoner, gastrointestinal, and central nervous system manifestations.
Fazile Hatipoğlu Erdem
doaj  

Delphi consensus: First‐line use of biologics and small molecules in hidradenitis suppurativa

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This Delphi Consensus study identified upgrade criteria for the use of biologics and small molecules as first‐line therapy in hidradenitis suppurativa (HS). European HS experts evaluated 16 clinical scenarios, voting on eligibility for therapy escalation.
Georgios Nikolakis   +54 more
wiley   +1 more source

Ptosis and Mass Like Lesions in Behçet’s Disease: A Rare Presentation

open access: yesThe Turkish Journal of Gastroenterology, 2018
In this article, we describe a case of neuro-Behçet’s disease presenting with unilateral ptosis and facial paresis due to an intracranial mass lesion. A 25-year-old male patient with a history of Behçet’s disease presented with headache, vertigo, double
Seher KIR   +4 more
doaj  

Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
The majority of bimekizumab‐treated patients shifted from severe to mild and moderate IHS4 stages, and nearly 25% achieved an IHS4 of 0 by Week 48. Bimekizumab led to clinically meaningful improvements across IHS4 outcome measures. These data highlight an opportunity to address the need for effective treatments against draining tunnels.
Thrasyvoulos Tzellos   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy